Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The Oncogenic role of miR-155 in breast cancer|
|Citation:||Cancer Epidemiology Biomarkers & Prevention, 2012; 21(8):1236-1243|
|Publisher:||Amer Assoc Cancer Research|
|Sam Mattiske, Rachel J. Suetani, Paul M. Neilsen, and David F. Callen|
|Abstract:||miR-155 is an oncogenic miRNA with well described roles in leukemia. However, additional roles of miR-155 in breast cancer progression have recently been described. A thorough literature search was conducted to review all published data to date, examining the role of miR-155 in breast cancer. Data on all validated miR-155 target genes was collated to identify biologic pathways relevant to miR-155 and breast cancer progression. Publications describing the clinical relevance, functional characterization, and regulation of expression of miR-155 in the context of breast cancer are reviewed. A total of 147 validated miR-155 target genes were identified from the literature. Pathway analysis of these genes identified likely roles in apoptosis, differentiation, angiogenesis, proliferation, and epithelial-mesenchymal transition. The large number of validated miR-155 targets presented here provide many avenues of interest as to the clinical potential of miR-155. Further investigation of these target genes will be required to elucidate the specific mechanisms and functions of miR-155 in breast cancer. This is the first review examining the role of miR-155 in breast cancer progression. The collated data of target genes and biologic pathways of miR-155 identified in this review suggest new avenues of research for this oncogenic miRNA.|
|Keywords:||Cell Line, Tumor; Animals; Humans; Breast Neoplasms; MicroRNAs; Cell Proliferation; Gene Expression Regulation, Neoplastic; Female|
|Rights:||©2012 American Association for Cancer Research|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.